GR3035587T3 - Thienobenzodiazepine derivatives for treatment of CNS disorders. - Google Patents

Thienobenzodiazepine derivatives for treatment of CNS disorders.

Info

Publication number
GR3035587T3
GR3035587T3 GR20010400431T GR20010400431T GR3035587T3 GR 3035587 T3 GR3035587 T3 GR 3035587T3 GR 20010400431 T GR20010400431 T GR 20010400431T GR 20010400431 T GR20010400431 T GR 20010400431T GR 3035587 T3 GR3035587 T3 GR 3035587T3
Authority
GR
Greece
Prior art keywords
treatment
cns disorders
alkyl
optionally substituted
thienobenzodiazepine
Prior art date
Application number
GR20010400431T
Other languages
Greek (el)
English (en)
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of GR3035587T3 publication Critical patent/GR3035587T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GR20010400431T 1992-05-29 2001-03-15 Thienobenzodiazepine derivatives for treatment of CNS disorders. GR3035587T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GR3035587T3 true GR3035587T3 (en) 2001-06-29

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400431T GR3035587T3 (en) 1992-05-29 2001-03-15 Thienobenzodiazepine derivatives for treatment of CNS disorders.

Country Status (21)

Country Link
EP (1) EP0582368B1 (enExample)
JP (1) JP3219541B2 (enExample)
CN (1) CN1043994C (enExample)
AT (1) ATE198891T1 (enExample)
AU (1) AU668159B2 (enExample)
CA (1) CA2097016A1 (enExample)
CZ (1) CZ282783B6 (enExample)
DE (1) DE69329887T2 (enExample)
DK (1) DK0582368T3 (enExample)
ES (1) ES2153373T3 (enExample)
FI (1) FI101538B1 (enExample)
GR (1) GR3035587T3 (enExample)
HU (1) HU218278B (enExample)
IL (1) IL105827A (enExample)
MX (1) MX9303124A (enExample)
MY (1) MY109943A (enExample)
NO (1) NO305125B1 (enExample)
NZ (1) NZ247703A (enExample)
PT (1) PT582368E (enExample)
RU (1) RU2125574C1 (enExample)
TW (1) TW268005B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
PL329217A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Pain relieving method
BR9708145A (pt) * 1996-03-25 1999-07-27 Lilly Co Eli Processo para tratamento de dor de enxaqueca
PL187926B1 (pl) * 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
AU720366B2 (en) * 1996-09-23 2000-06-01 Eli Lilly And Company Olanzapine dihydrate D
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
CA2882560C (en) 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptens of risperidone and paliperidone for use in immunoassays
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
PL2888373T3 (pl) 2012-08-21 2018-08-31 Janssen Pharmaceutica Nv Przeciwciała dla arypiprazolu i ich zastosowanie
PT3305784T (pt) 2012-08-21 2020-10-23 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
PL2888286T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
ES2870004T3 (es) 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
ES3057437T3 (en) 2012-08-21 2026-03-02 Janssen Pharmaceutica Nv Antibodies to olanzapine haptens and use thereof
ES2701062T3 (es) * 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
CN108368180B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 喹硫平的抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569730A5 (enExample) * 1972-04-04 1975-11-28 Wander Ag Dr A
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US4061752A (en) * 1975-08-06 1977-12-06 Sandoz Ltd. 6-Piperazino-11-methylene-dibenzazepines[b,e]
SE7610219L (sv) * 1975-09-24 1977-03-25 Sandoz Ag Nya dibenso /b,e//1,4/ diazepiner
CH624682A5 (enExample) * 1976-11-10 1981-08-14 Sandoz Ag
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
IL105827A0 (en) 1993-09-22
CZ102493A3 (en) 1993-12-15
MY109943A (en) 1997-10-31
IL105827A (en) 1997-02-18
DK0582368T3 (da) 2001-02-05
CN1043994C (zh) 1999-07-07
DE69329887D1 (de) 2001-03-01
JP3219541B2 (ja) 2001-10-15
FI101538B (fi) 1998-07-15
NO931917D0 (no) 1993-05-26
FI101538B1 (fi) 1998-07-15
CA2097016A1 (en) 1993-11-30
HU9301579D0 (en) 1993-09-28
HU218278B (en) 2000-07-28
CN1085903A (zh) 1994-04-27
PT582368E (pt) 2001-05-31
NO931917L (no) 1993-11-30
TW268005B (enExample) 1996-01-11
CZ282783B6 (cs) 1997-10-15
ATE198891T1 (de) 2001-02-15
JPH0687862A (ja) 1994-03-29
NO305125B1 (no) 1999-04-06
FI932445A0 (fi) 1993-05-28
FI932445L (fi) 1993-11-30
ES2153373T3 (es) 2001-03-01
EP0582368B1 (en) 2001-01-24
HUT66180A (en) 1994-09-28
DE69329887T2 (de) 2001-05-23
EP0582368A1 (en) 1994-02-09
AU668159B2 (en) 1996-04-26
MX9303124A (es) 1993-11-01
NZ247703A (en) 1995-07-26
AU3980793A (en) 1993-12-02
RU2125574C1 (ru) 1999-01-27

Similar Documents

Publication Publication Date Title
TW268005B (enExample)
IL100572A (en) Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
EP0324387A3 (en) Composition for treatment of ischemic disorder in organs
ZA896067B (en) Chemical compounds
IL110151A0 (en) Amide and urea derivatives and pharmaceutical compositions containing the same
GR3005779T3 (enExample)
IL111275A0 (en) Galanthamine derivatives, a process for their preparation and their use as medicaments
HUT55385A (en) Process for producing 3-piperazinyl-benzazol derivatives and pharmaceutical compositions containing them as active components
GR3020190T3 (en) Diclofenac choline salt, a method for the preparation thereof and pharmaceutical compositions containing it
EP1123703A4 (en) IMMUNOMODULATOR DRUG COMPOSITION
EP0103320A3 (en) Acetylsalicylic acid thioesters, a process for their preparation and pharmaceutical compositions containing them
HU9400908D0 (en) Pharmaceutical compositions for treatng skin disorders
GB8903036D0 (en) Chemical compounds
AU657423B2 (en) Novel piperidine derivatives and process for preparation thereof
IE890199L (en) Antibiotic a 42867 derivative
TW265342B (enExample)
DE3867494D1 (de) Fluor enthaltende vitamin-d2-derivate.
IL109227A0 (en) Leustroducsin h, pharmaceutical composition containing the same, and processes for the preparation thereof

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees